ARTICLE | Company News
SanBio, Dainippon Sumitomo deal
October 11, 2010 7:00 AM UTC
SanBio granted Dainippon Sumitomo an option to license exclusive rights to co-develop and market SB623 for stroke recovery in the U.S. and Canada. SB623 consists of allogeneic cells derived from the ...